Pfizer will stop the development of its twice-daily weight loss pill due to adverse side effects.
Share:
More In Business
Who Decides? Who Profits? Who Pays? Inside Trump's D.C. Projects
David Fahrenthold, investigative reporter for The New York Times, examines rising costs, contracts, and transparency concerns in Trump's D.C. projects.
Is The Fed About to Make Its Biggest Move Yet?
Megan Leonhardt, Senior Economics Writer at Barron's, breaks down sticky inflation, Fed policy, interest rates and what they mean for consumers.
The Market Impact: Middle East Updates This Week
Rob Schroeder, Washington Bureau Chief at MarketWatch, examines the U.S.-Iran ceasefire, market reaction, oil prices and risks ahead.
The Retail Revival Nobody Saw Coming: Inside Bed Bath & Beyond’s Big Comeback
Amy Sullivan, CEO of Bed Bath & Beyond, joins us to discuss the brand’s comeback, its Container Store partnership and the future of home shopping.
Pacsun’s Wild Comeback: How The Brand Won Over Gen Z Again
Pacsun CEO Brieane Olson reveals how the iconic retailer reinvented itself for a new generation obsessed with culture and authenticity.
